Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Ventilatory Depression, Postoperative Re...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In this randomized-controlled trial the investigators will examine the effect of oxygen supplementation on the recovery of breathing for 90 minutes in the immediate post-anesthesia period starting from extubation of the trachea.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Other: Oxygen Gas for Inhalation — Oxyhemoglobin saturation (SpO2) higher than 96% vs SpO2 between 90% and 94%.

Primary Outcomes

  • Transcutaneous partial pressure of carbon dioxide (TcPCO2) (Ninety -minute period beginning immediately post-anesthesia.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-10-04
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Stanford University
Principal Investigators:
  • Anthony Doufas, MD, PhD (PRINCIPAL_INVESTIGATOR) - Professor, Department of Anesthesiology, Stanford University Medical School
Contact Information
Study Contact:
Anthony Doufas, MD, PhD
650-498-7699
agdoufas@stanford.edu
Anthony Doufas, MD, PhD
(650) 498-7699
agdoufas@stanford.edu
Stanford University School of Medicine
Anthony Doufas, MD, PhD
Stanford University School of Medicine
Interventions
  • Other: Oxygen Gas for Inhalation — Oxyhemoglobin saturation (SpO2) higher than 96% vs SpO2 between 90% and 94%.
Study Locations (1 sites)
Stanford University School of Medicine, Stanford, California 94305 United States
Eligibility Criteria
Inclusion Criteria: * American Society of Anesthesiologists (ASA) physical status I-III * Body mass index (BMI) less than 40 kg/m2 * Scheduled to undergo robotic-assisted radical laparoscopic nephrectomy or prostatectomy. Exclusion Criteria: * Patients with a diagnosis of chronic obstructive pulmonary disorder (COPD), severe neurological, cardiopulmonary, psychiatric, or untreated thyroid disorder * Chronic pain condition that is being treated with opioids * Patients with a hematocrit lower than 30% at the end of surgery, or those with an excessive blood loss, requiring transfusion of blood products during surgery.
Conditions Long-term Effects of Cancer Treatment, L...
Phase NA
Enrollment 182
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The number of breast cancer survivors is growing. More cured women are becoming long-term survivors of breast cancer (LS-BC) at least 5 years after diagnosis and after treatment has been completed. Some of these LS-BC return to daily life without any problems; however, in many cases, they experience and have to deal with physical sequelae (chronic fatigue, pain, etc.) psychological sequelae (anxiety, depression, fear of recurrence, etc.) and social sequelae (altered interpersonal relationships, difficulty in returning to work, etc.). For many LS-BC, these health problems are not being met by health professionals. Thus there is a need to promote greater continuity and coordination between specialized oncology care and primary health care in order to enhance specific follow-up of these women in the community. However, the role of the primary health care team in the provision of care in the long-term cancer survival is not clearly defined and few actions have been aimed at improving care activities, standardizing procedures and protocols, developing documentation and registries and updating the training of health care professionals. Therefore, this study aim to design, implement, and evaluate a web based tailored intervention, using artificial intelligence, to improve the quality of life of long-term breast cancer survivors, and self-efficacy for the management of late sequelae from primary care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: CUMACA-M Program — The CUMACA-M Program will focus on a web-based tailored intervention, using artificial intelligence, for Long-Term Survivors of Breast Cancer. It will be structured into modules related to the specific needs of LS-BS, including physical, psychological, and social needs

Primary Outcomes

  • Quality of life Cancer Survivor (QOL-CS) (Changes from baseline, 3-months, 6 months, and 9 month)
  • Self-Efficacy for Managing Chronic Disease (Changes from baseline, 3-months, 6 months, and 9 month)
  • Sociodemographic data of LS-BC (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-12-15
Completion: 2025-11
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 182 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cristina García-Vivar
Collaborators: Instituto de Salud Carlos III
Principal Investigators:
  • Cristina Garcia Vivar, PhD (PRINCIPAL_INVESTIGATOR) - Universidad Pública de Navarra
Contact Information
Study Contact:
Cristina García-Vivar, PhD
+34948166150
cristina.garciavivar@unavarra.es
Interventions
  • Other: CUMACA-M Program — The CUMACA-M Program will focus on a web-based tailored intervention, using artificial intelligence, for Long-Term Survivors of Breast Cancer. It will be structured into modules related to the specific needs of LS-BS, including physical, psychological, and social needs
Study Locations (1 sites)
Public University of Navarre, Pamplona, 31008 Spain
Eligibility Criteria
Inclusion Criteria: * having been diagnosed with breast cancer * having completed active oncological treatments (chemotherapy and/or radiotherapy) in a period of time greater than five years, * be free of disease at the time of data collection * be a woman and over 18 years of age * have knowledge of Internet use. Exclusion Criteria: * Women with a diagnosis of cancer other than breast cancer * Recurrence of cancer or metastasis that causes a new treatment * Being in active treatment for recurrence or new cancer * Being a man
Conditions Type 2 Diabetes Treated With Insulin, Pr...
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to perform a randomized controlled trial among 180 pregnant women with type 2 diabetes mellitus (T2DM) comparing continuous glucose monitor (CGM) use to the standard of care of multiple daily fingerstick glucose monitoring and its impact on large for gestational age infants, maternal glycemic control, patient satisfaction, and additional adverse perinatal outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Device: Continuous Glucose Monitor — Continuous Glucose Monitor
  • Device: Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose) — Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)

Primary Outcomes

  • Large for Gestational Age Infant (Within 2 hours of birth)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-23
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Massachusetts, Worcester
Principal Investigators:
  • Gianna L Wilkie, MD (PRINCIPAL_INVESTIGATOR) - University of Massachusetts, Worcester
Contact Information
Study Contact:
Gianna L Wilkie, MD
7743642523
Gianna.Wilkie@umassmemorial.org
Heidi Leftwich, DO
Heidi.Leftwich@umassmemorial.org
Gianna L Wilkie, MD
508-334-4067
Gianna.Wilkie@umassmemorial.org
University of Massachusetts Memorial Medical Center
Interventions
  • Device: Continuous Glucose Monitor — Continuous Glucose Monitor
  • Device: Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose) — Routine Capillary Blood Glucose Monitoring (Fingerstick Glucose)
Study Locations (1 sites)
University of Massachusetts Memorial Medical Center, Worcester, Massachusetts 01605 United States
Eligibility Criteria
Inclusion Criteria: Women will be deemed eligible for the study by the following inclusion criteria: * 1\) age greater than or equal to 18 years old * 2\) singleton gestation less than or equal to 14 weeks at initial obstetric visit * 3\) established diagnosis of T2DM by laboratory criteria including hemoglobin A1c ≥6.5%, oral glucose tolerance test ≥200 mg/dL, or fasting plasma glucose ≥126 mg/dL * 4\) receiving prenatal care at UMASS Memorial Health Care (UMMHC) and plans to deliver at UMMHC * 5\) able and willing to provide informed consent Exclusion Criteria: Women will be deemed ineligible for the study based on the following exclusion criteria: * 1\) known diagnosis of type 1 diabetes or gestational diabetes * 2\) plan to receive prenatal care or delivery outside of UMMHC * 3\) inability to provide informed consent * 4\) multifetal gestation

OSU6162 in Bipolar Depression (OBID)

NCT05296356
Recruiting
Conditions Bipolar Depression
Phase PHASE2
Enrollment 22
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

An explorative, open label, single armed, flexible dose, single center, phase IIa study of 8 weeks, initiated in subjects with bipolar depression. The study will consist of 9 visits and 1 safety visit. Subjects with a primary diagnosis of bipolar disorder (type 1 or 2) currently in an acute depressive phase (i.e. bipolar depression) and being on stable medication with at least one mood stabilizer.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: OSU6162 — OSU6162

Primary Outcomes

  • Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) at endpoint [Day 60]. (Endpoint at 60 days treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-10-25
Completion: 2029-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 22 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Göteborg University
Collaborators: Arvid Carlsson Research AB
Contact Information
Study Contact:
Elias Eriksson, Professor
+ 46 709 555055
elias.eriksson@neuro.gu.se
Steinn Steingrimsson, MD, PhD
+ 46 722 448372
steinn.steingrimsson@vgregion.se
Michael Ioannou, MD
+46 70 082 38 20
michael.ioannou@vgregion.se
Sahlgrenska university hospital/Östra
Interventions
  • Drug: OSU6162 — OSU6162
Study Locations (1 sites)
Sahlgrenska university hospital/Östra, Gothenburg, SE 405 30 Sweden
Eligibility Criteria
Inclusion Criteria: 1. Signed informed consent 2. Voluntary admission to the psychiatric ward prior or directly after the screening point 3. Age: 18-65 on the day of screening 4. Meeting DSM-5 criteria for a depressive episode in Bipolar Disorder type I or type II, as confirmed by the Mini International Neuropsychiatric Interview (MINI) 5. Displaying a sum score of ≥10 on the Bech 6-item subscale of the Hamilton Depression rating Scale. 6. Treatment with a stable dose of a mood stabilizer since at least 4 weeks before screening: lithium s-conc\> 0,45 mmol/L; \>lamotrigine dose 100 mg/d; \>valproate dose \> 900 mg/d, \>carbamazepine concentration \>20 mmol/L 7. In female patients of childbearing potential: negative result of a pregnancy test and a method of contraception with a failure rate of less than 1 %. Women of childbearing potential must, for inclusion, use a highly efficient method of contraception, i.e. a method with a failure rate of less than 1% (e.g. sterilization, hormone implants, hormone injections, some intrauterine devices, or vasectomy in partner). 8. Male patients must agree to use condoms during the study and for 2 weeks after the end of the study/last dose of IMP, unless their partner is using a highly efficient method of contraception, as described above. Exclusion Criteria: 1. Ongoing compulsory care. 2. Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property. 3. Previously diagnosed or meeting MINI criteria at interview for obsessive-compulsive disorder or post-traumatic stress disorder. 4. A previous diagnosis of a personality disorder, autism, ADHD, or intellectual disability. 5. A history of substance/alcohol abuse within 2 years prior to screening. 6. Any other previously diagnosed or suspected CNS disorder that according to the investigator renders the patient unsuitable for participation in the trial (such as dementia, brain injury, and epilepsy). 7. Young Mania Rating Scale (YMRS) total score of \>12 at screening or at any time during the trial. 8. Any somatic illness that according to the investigator renders the patient unsuitable for participation in the trial. 9. Any signs or symptoms of somatic illness resulting from assessment of vital signs, physical examination, clinical laboratory tests or 12- lead ECG that according to the investigator renders the patient unsuitable for participation for safety reasons, including a QTc-time on ECG exceeding 450 ms in men and 460 ms in women. 10. Any factor that according to the investigator renders it unlikely that the patient will comply with the instructions regarding treatment, visits etc. 11. Any change in medication (including dosage) of an antidepressant drug or a mood stabiliser within 4 weeks prior to screening or at any time during the trial. 12. Ongoing treatment with potent cytochrome P450 enzyme inhibitors (e.g., bupropion, fluvoxamin, ketoconazol, itraconazole, telitromycin, clarithromycin, protease inhibitors, quinidine, and terbinafine). 13. Ongoing treatment with drugs displaying a narrow therapeutic window - with the exception of lithium - where either reduced or increased serum levels are potentially harmful (including but not limited to warfarin, other anticoagulants, digoxin. other antiarrythmics, anticonvulsants when prescribed for treatment of epilepsy but not when prescribed for bipolar disorder, cyclosporine, and immunosuppressants). 14. Ongoing treatment with drugs with dopaminergic synapses as primary site of action (e.g., antipsychotics, bupropion, central stimulants, and drugs for Parkinson's disease). 15. No observed beneficial effect of treatment and a symptom severity that by the investigator's assessment would render continued participation unethical. 16. Previous intake of OSU6162. 17. Current participation in another clinical trial. 18. Nursing women.
Conditions Early-stage Breast Cancer
Phase NA
Enrollment 300
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, multi-center, open-label cohort study, with 3 years disease free survival(DFS) as the primary endpoint. We optimize post-operation adjuvant therapy for early stage breast cancer based on the MRD strategy: patients with clinical high risk or post-operation 1st MRD tested positive will receive intensive adjuvant therapy, while patients with low clinical risk and post-operation 1st MRD tested negative will receive standard adjuvant therapy, and the treatment regimens will be adjusted every 3 months according to the change of MRD status. About 100 TNBC patients, 100 HER2+ patients, and 100 ER+ patients are planned to be enrolled.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: The MRD strategy for high risk or MRD+ TNBC patients — Standard adjuvant chemotherapy + additional chemotherapy: * BRCA positive patients: standard adjuvant chemotherapy + olaparib * BRCA negative patients: standard adjuvant chemotherapy + capecitabine In the period of once 3 months follow-up, if MRD remains positive, the additional chemotherapy will be changed for at most once.
  • Other: The MRD strategy for high risk or MRD+ HER2+ patients — Standard adjuvant chemotherapy + intensive targeted therapy: * Neoadjuvant therapy non-pCR patients: standard adjuvant chemotherapy completed+ T-DM1/HP * Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy completed + HP * Adjuvant therapy patients: AC-T/TCb + HP In the period of once 3 months follow-up, if MRD remains positive, the intensive targeted therapy will be changed for at most once.
  • Other: The MRD strategy for high risk or MRD+ ER+ patients — Standard adjuvant chemotherapy + intensive endocrine therapy: * Premenopausal patients: Standard adjuvant chemotherapy followed by OFS + TAM/TOR, OFS + ANA/LET/EXE, or OFS + ANA/LET/EXE + Abemaciclib. * Postmenopausal: Standard adjuvant chemotherapy followed by ANA/LET/EXE + Abemaciclib. In the period of once 3 months follow-up, if MRD remains positive, the intensive endocrine therapy will be changed for at most once.
  • Other: The MRD strategy for low risk and MRD- TNBC patients — Standard adjuvant chemotherapy: AC-T/TC/TCb/AC. In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant therapies listed in "The MRD strategy for high risk or MRD+ TNBC patients "will be added for at most twice.
  • Other: The MRD strategy for low risk and MRD- HER2+ patients — Standard adjuvant chemotherapy + standard targeted therapy: * Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy (AC-T/TC/TCb) completed + H. * Adjuvant therapy patients: AC-T/TC/TCb/wP + H. In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant targeted therapies listed in "The MRD strategy for high risk or MRD+ HER2+ patients "will be added for at most twice.
  • Other: The MRD strategy for low risk and MRD- ER+ patients — Standard adjuvant chemotherapy + standard endocrine therapy: * Premenopausal patients: Standard adjuvant chemotherapy followed by TAM/TOR. * Postmenopausal patients: Standard adjuvant chemotherapy followed by ANA/LET/EXE. In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant endocrine therapies listed in "The MRD strategy for high risk or MRD+ ER+ patients "will be added for at most twice.

Primary Outcomes

  • 3 years disease free survival(DFS) (From date of radical surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-03-24
Completion: 2027-03-24
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators: Beijing Huanxing Cancer Hospital, Chinese Academy of Medical Sciences
Principal Investigators:
  • Fei Ma (PRINCIPAL_INVESTIGATOR) - Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Fei Ma
86-10-87788060
drmafei@126.com
Hongnan Mo
86-10-87788120
Fei Ma
86-10-87788060
drmafei@126.com
Cancer Hospital, Chinese Academy of Medical Sciences
Interventions
  • Other: The MRD strategy for high risk or MRD+ TNBC patients — Standard adjuvant chemotherapy + additional chemotherapy: * BRCA positive patients: standard adjuvant chemotherapy + olaparib * BRCA negative patients: standard adjuvant chemotherapy + capecitabine In the period of once 3 months follow-up, if MRD remains positive, the additional chemotherapy will be changed for at most once.
  • Other: The MRD strategy for high risk or MRD+ HER2+ patients — Standard adjuvant chemotherapy + intensive targeted therapy: * Neoadjuvant therapy non-pCR patients: standard adjuvant chemotherapy completed+ T-DM1/HP * Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy completed + HP * Adjuvant therapy patients: AC-T/TCb + HP In the period of once 3 months follow-up, if MRD remains positive, the intensive targeted therapy will be changed for at most once.
  • Other: The MRD strategy for high risk or MRD+ ER+ patients — Standard adjuvant chemotherapy + intensive endocrine therapy: * Premenopausal patients: Standard adjuvant chemotherapy followed by OFS + TAM/TOR, OFS + ANA/LET/EXE, or OFS + ANA/LET/EXE + Abemaciclib. * Postmenopausal: Standard adjuvant chemotherapy followed by ANA/LET/EXE + Abemaciclib. In the period of once 3 months follow-up, if MRD remains positive, the intensive endocrine therapy will be changed for at most once.
  • Other: The MRD strategy for low risk and MRD- TNBC patients — Standard adjuvant chemotherapy: AC-T/TC/TCb/AC. In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant therapies listed in "The MRD strategy for high risk or MRD+ TNBC patients "will be added for at most twice.
  • Other: The MRD strategy for low risk and MRD- HER2+ patients — Standard adjuvant chemotherapy + standard targeted therapy: * Neoadjuvant therapy pCR patients: standard adjuvant chemotherapy (AC-T/TC/TCb) completed + H. * Adjuvant therapy patients: AC-T/TC/TCb/wP + H. In the period of once 3 months follow-up, if MRD turns positive, additional adjuvant targeted therapies listed in "The MRD strategy for high risk or MRD+ HER2+ patients "will be added for at most twice.
Study Locations (3 sites)
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100021 China
Beijing Huanxing Cancer Hospital, Beijing, Beijing Municipality China
Cancer Hospital, Chinese Academy of Medical Sciences, Hebei Center, Langfang, Hebei China
Eligibility Criteria
Inclusion Criteria: * Subjects aged ≥18 years (inclusive). * Histologically confirmed, perioperative invasive breast cancer that is resectable without metastasis(stage I-III). * No anti-breast cancer systematic therapy received, and planning to receive surgery and systemic therapy. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * With Adequate Organ Function: a. Bone marrow function: Hemoglobin ≥ 10 g/dL; Absolute leucocyte count ≥ 4×10\^9/L; Absolute neutrophil count ≥ 1.5×10\^9/L; Platelets ≥ 100 × 10\^9/L; b. Liver function (based on the normal values specified by study site): Serum total bilirubin ≤ 1.5 × the upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; c. Renal function (based on the normal values specified by study site): Serum creatinine ≤ 1.5 × ULN. * The patients voluntarily signed an informed consent form. Exclusion Criteria: * Known to have other aggressive malignant tumor that is progressing or requires systemic treatment in the past 5 years (does not exclude subjects with skin basal cell carcinoma, skin squamous cell carcinoma, breast ductal carcinoma in situ or cervical cancer in situ that has received curative treatment). * Have a clear history of neurological or mental disorders, including epilepsy or dementia, etc.; have a history of psychotropic drug abuse or drug abuse. * Known history of allergy to the drug components in MRD strategy; history of immunodeficiency, or history of organ transplantation. * There are other concomitant diseases that seriously threaten the patient's safety or affect the patient's completion of the study, such as serious infection, liver disease, cardiovascular disease, kidney disease, respiratory disease or uncontrolled diabetes or dyslipidemia. * Female patients during pregnancy or lactation. * The investigator determines that subjects are not appropriate to participate in the study due to other factors.
Conditions Cardiovascular Diseases, Chronic Kidney ...
Phase NA
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study tests the efficacy of a dyadic intervention to mitigate the adverse health consequences of adults with pre-existing chronic health conditions and their informal carepartners (IC). Socioeconomically disadvantaged, older, and people from rural regions are more likely burdened with greater rates of chronic diseases such as diabetes, hypertension, chronic kidney disease, cardiovascular disease, and stroke.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM) — The intervention consists of two planning sessions with the dyad (over 2 weeks) followed by eight topic-guided sessions delivered the RN-CHW team over 12 weeks (weekly the first 4 weeks, then bi-weekly) (Table 3). Key components of these televisits include risk mitigation, chronic disease management, medication adherence, family functioning/support, and community and health systems resource identification and referral with ongoing goal planning. The RN-CHW will meet weekly for progress review, follow up planning, and setting up anticipatory guidance for the next session with the dyads. The RN and CHW will also review IC or survivor dissatisfaction and other issues that require more immediate attention. RN-CHW planning will be assessed to make sure each televisit remain topic focused yet incorporates flexibility to suit the needs of each dyad.

Primary Outcomes

  • Change in patient-reported outcomes measurement information system (PROMIS) Global Health Scale (0, 4, 7 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-01-03
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of South Carolina
Collaborators: National Institute of Nursing Research (NINR)
Principal Investigators:
  • Gayenell S Magwood, PhD (PRINCIPAL_INVESTIGATOR) - University of South Carolina
Contact Information
Study Contact:
Study PI
8037779160
magwoodg@sc.edu
Program Coordinator
(803) 576-7787
Gayenell S Magwood, PhD
8037779160
magwoodg@sc.edu
University of South Carolina
Interventions
  • Behavioral: Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM) — The intervention consists of two planning sessions with the dyad (over 2 weeks) followed by eight topic-guided sessions delivered the RN-CHW team over 12 weeks (weekly the first 4 weeks, then bi-weekly) (Table 3). Key components of these televisits include risk mitigation, chronic disease management, medication adherence, family functioning/support, and community and health systems resource identification and referral with ongoing goal planning. The RN-CHW will meet weekly for progress review, follow up planning, and setting up anticipatory guidance for the next session with the dyads. The RN and CHW will also review IC or survivor dissatisfaction and other issues that require more immediate attention. RN-CHW planning will be assessed to make sure each televisit remain topic focused yet incorporates flexibility to suit the needs of each dyad.
Study Locations (1 sites)
University of South Carolina, Columbia, South Carolina 29208 United States
Eligibility Criteria
Inclusion Criteria: * Male and female * Living in a Medically Underserved Area and/or a designated rural area of South Carolina * ≥ 18 years and above * A previous diagnosis of one or more of the following conditions: type 2 diabetes, hypertension, cardiovascular disease, chronic kidney disease, or stroke (\>3 months) -Carepartner inclusion criteria * Male and female * ≥ 18 years and above * Must live on the same property or community, preferably within a 40-mile radius of the patient (dyad member) * Primarily responsible for care provision and/or care/social support in the home (i.e., is not paid for services) Exclusion Criteria: • Enrolled in related clinical trials .No member of dyad has at least one of the included chronic health conditions
Conditions Type 2 Diabetes
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is an open label, exploratory pilot study that will assess the effects of dual site focused pulsed ultrasound treatment on glycemic parameters in subjects with T2DM.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Ultrasound Delivery — A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to both, the portal region of the liver and the superior mesenteric plexus.

Primary Outcomes

  • Number of Hepatic Adverse Events - Elevation of liver transaminases AST / ALT. (2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-11-01
Completion: 2026-05
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: GE Healthcare
Principal Investigators:
  • Raimund Herzog, MD (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Alice Hahn
475-321-0504
alice.hahn@yale.edu
Alice Hahn
475-321-0504
diabetes.research@yale.edu
Yale-New Haven Hospital
Raimund Herzog, MD
Yale-New Haven Hospital
Interventions
  • Device: Ultrasound Delivery — A General Electric LOGIQ E10 ultrasound machine with a C1-6-XD clear probe, will be used to selectively deliver pulsed ultrasound to both, the portal region of the liver and the superior mesenteric plexus.
Study Locations (1 sites)
Yale-New Haven Hospital, New Haven, Connecticut 06510 United States
Eligibility Criteria
Inclusion Criteria: 1. Male or female subjects with a diagnosis of type 2 diabetes ≥ 3 months. 2. Age ≥ 21 and ≤ 75 years. 3. Currently on a stable treatment regimen of oral anti-diabetic drugs and not currently prescribed for medication escalation. Oral anti-diabetic drugs are limited to one or more of the following: * Metformin * Sulfonylureas * Meglitinides * Thiazolidinediones 4. HbA1c \> 7.0% and \< 10% by local laboratory analysis. 5. Body Mass Index (BMI) ≥ 18 to ≤ 40.0 kg/m2. 6. Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Principal Investigator. 7. Female subjects must be non-pregnant and non-lactating and have a negative serum pregnancy test at screening and before the ultrasound session. 8. Ability to provide written informed consent. Exclusion Criteria: 1. History or current diagnosis with T1DM or T2DM subjects on insulin, DPP-4 inhibitors, GLP agonists. 2. A subject who is already indicated for medication escalation of their current diabetic therapy. 3. A subject who has manifestations of advanced complications from poorly controlled or longstanding diabetes such as diabetic retinopathy, diabetic neuropathy and cardiovascular complications including, but not limited to coronary artery disease, peripheral vascular disease, or cerebrovascular disease such as transient ischemic attack \[TIA\], cerebral infarct, or cerebral hemorrhage. 4. History or current diagnosis of cardiac dysrhythmias or heart disease, defined as symptomatic heart failure (New York Heart Association class III or IV), myocardial infarction, unstable angina requiring medication. 5. Invasive cardiovascular procedure, such as coronary artery bypass graft surgery (CABG), or angioplasty/percutaneous coronary intervention (PCI) within 6 months of screening. 6. History of recurrent severe hypoglycemia (more than 1 event ≤ 6 month) 7. Subjects with clinically active malignancy 8. History of renal disease or abnormal kidney function tests at Screening (glomerular filtration rate \[GFR\] \< 60 mL/min/1.73m2 as estimated using the MDRD equation). 9. History or active hepatic disease or clinically significant abnormal hepatic function tests at Screening suggestive of hepatic impairment (e.g., ALT and/or AST \>2 x ULN, GGT \>2 x ULN, total bilirubin \> 1 x ULN). 10. Subjects with a history or presence of any psychiatric disorder that, in the opinion of the Principal Investigator, might confound the results of the trial or pose additional risk in administering the investigational product to the subject. 11. Personal or family history of hypercoagulability or thromboembolic disease, including deep vein thrombosis and/or pulmonary embolism (PE) 12. History of surgical treatment for obesity (bariatric surgery, gastric banding, etc.) or any other gastrointestinal surgery (including appendectomy, cholecystectomy), any malabsorption disorder, severe gastroparesis, any GI procedure for weight loss (including LAP-BAND®), as well as clinically significant gastrointestinal disorders (e.g. peptic ulcers, severe GERD) at Screening. 13. History of any major surgery within 3 months prior to screening. 14. Any nerve stimulation study or implanted stimulator, including previously or currently implanted vagus nerve stimulator, previously or currently implanted spinal cord stimulator, other implanted electronic medical device, such as implanted pacemaker or cardioverter/ defibrillator (AICD) or history of seizures. 15. Participation in an investigational study within 30 days prior to dosing or 5 half-lives within the last dose of the investigational product given during the investigational study, whichever is longer. 16. Current use of any drugs (other than current treatment for diabetes mellitus) that are known to interfere with glucose or insulin metabolism as stated below in table prohibited medication. 17. Thyroid hormone use is not allowed unless medication is given on a stable dose for at least 3 months prior to screening. 18. Subject is unable to tolerate adhesive tape or has any unresolved adverse skin reaction in the area of the glucose sensor placement. 19. Implanted pacemaker or cardioverter/defibrillator (AICD). 20. History of any active infection, incl. COVID19 (as ruled out by negative PCR test), except mild viral disease, such as common cold, within 30 days prior to screening. 21. Known history or positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), human immunodeficiency virus type 1 (HIV-1) or type 2 (HIV-2). 22. History of any recent traumatic injury, including intracerebral hemorrhage and visceral injury. 23. Donation or loss of \> 500 mL of blood or blood product within 2 months prior to screening. 24. Mental incapacity, unwillingness or language barriers precluding adequate understanding and to follow verbal commands during the ultrasound session or cooperation. 25. An abdominal ultrasound scan or exam within 1 month prior to screening and/or any pre-planned ultrasound examinations during the study, or the need to participate in any unplanned outside ultrasound procedures during study. 26. Use of the agents listed in Prohibited Medications Table below (prescription or nonprescription) is prohibited until completion of all study activities. 27. Identification of risk of hypoglycemia or severely uncontrolled diabetes in screening visit metabolic assessments (CGM, OGTT, and fasting blood draws)
Conditions Preeclampsia
Phase PHASE3
Enrollment 58
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is prospective, single arm group ,open label, and multicenter trial (with two parallel-group \[Hydroxychloroquine 200mg with Aspirin 100mg or Aspirin 100mg\])

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Hydroxychloroquine — Hydroxychloroquine 200mg with Aspirin 100mg

Primary Outcomes

  • Composite morbidity (gestational period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2022-05-31
Completion: 2028-12-31
Eligibility
Age: 19 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 58 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yoo-min Kim
Collaborators: Ministry of Health & Welfare, Korea
Principal Investigators:
  • Yoo-min Kim, MD (PRINCIPAL_INVESTIGATOR) - Chung-Ang University Gwangmyeong Hospital
Contact Information
Study Contact:
Yoo-min Kim, MD
+82-2-6299-1661
yoominkim@cau.ac.kr
Yoo-min Kim, MD
Chung-Ang University Hospital
Interventions
  • Drug: Hydroxychloroquine — Hydroxychloroquine 200mg with Aspirin 100mg
Study Locations (1 sites)
Chung-Ang University Hospital, Seoul, 06973 South Korea
Eligibility Criteria
Inclusion Criteria: 1. The singleton pregnant women aged from 19 to 50 years 2. Includes at least one factors of the below ① History of preeclampsia ② History of fetal growth restriction ③ History of intrauterine fetal death 3. Women who have agreed to enroll in the study and given their informed consent Exclusion Criteria: 1. Indication to a treatment according to the severe cardiovascular, immune, respiratory, gastrointestinal/liver and biliary system, kidney and urinary system, nervous system, musculoskeletal system, psychiatric, infectious disease and malignancy (However, the participation of the trial is allowed by the investigator based on medically necessary.) 2. Previous inclusion in other intervention study within 3 months of screening (except for non-interventional observational studies) 3. Major malformation of the fetus is diagnosed at 11-13 weeks of gestation 4. Elevated blood concentrations of creatinine more than double the normal value 5. Elevated blood concentrations of liver transaminases (AST(GOT) or ALT(GPT)) more than three times the normal value 6. Conditions related with aspirin treatment * Previous exposure within 28 days of screening * Previous NSAID exposure within 28 days of screening * Bleeding disorder (von Willebrand's disease, peptic ulceration) * Hypersensitivity to aspirin 7. Conditions related with hydroxychloroquine treatment * Previous exposure within 28 days of screening * Hypersensitivity to hydroxychloroquine and 4-aminoquinoline compounds * Maculopathy * Medications that has potential for visual disturbance * Women who have potential for changes in the retina or visual impairment by 4-aminoquinoline compounds * Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption * Prolonged QT interval on EKG (congenital or acquired) or The risk factors of QT prolongation (heart failure, arrhythmia, myocardial ischemia) * Low level of potassium in the blood * Low level of magnesium in the blood 8. Not suitable for participant based on medical evidence by investigator
Conditions Breast Cancer
Phase NA
Enrollment 100
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In this ABLATIVE-2 trial, low-risk breast cancer patients will be treated with MRI-guided single dose preoperative partial breast radiotherapy to assess the rate of pathologic complete response after an interval of six to twelve months between radiotherapy and surgery. Response monitoring will be assessed using MRI and markers in blood and tumor tissue to enable prediction of pathologic response.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Single dose ablative radiotherapy — Patients will receive a single dose of 20Gy/15Gy on the gross tumor volume and clinical tumor volume respectively, in the context of pre-operative partial breast irradiation

Primary Outcomes

  • Pathologic complete response (12 months after radiotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-08-24
Completion: 2037-12
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Amsterdam UMC, location VUmc
Collaborators: Dutch Cancer Society
Principal Investigators:
  • Desirée van den Bongard, MD, PhD (PRINCIPAL_INVESTIGATOR) - Amsterdam UMC, location VUmc
Contact Information
Study Contact:
Janneke van Roij, MD
+31 6 11094077
j.s.vanroij@amsterdamumc.nl
Desirée van den Bongard, MD, PhD
h.j.vandenbongard@amsterdamumc.nl
Gillian Lamoury, MD
+61400415836
Gillian.Lamoury@health.nsw.gov.au
GenesisCare
Interventions
  • Radiation: Single dose ablative radiotherapy — Patients will receive a single dose of 20Gy/15Gy on the gross tumor volume and clinical tumor volume respectively, in the context of pre-operative partial breast irradiation
Study Locations (7 sites)
GenesisCare, Sydney, Australia
Flevoziekenhuis, Almere Stad, Netherlands
Ziekenhuis Amstelland, Amstelveen, Netherlands
Amsterdam UMC, Amsterdam, Netherlands
Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands
Radboud UMC, Nijmegen, Netherlands
Zaans Medisch Centrum, Zaandam, Netherlands
Eligibility Criteria
Inclusion Criteria: * WHO performance scale ≤2. * Females at least 50 years of age with unifocal cT1N0 breast cancer on mammography, ultrasound and MRI. * Patients with an indication for chemotherapy or HER2-targeted therapy according to Dutch National Oncoline Guidelines or own hospital protocols are not eligible. Patients with an indication for endocrine therapy are eligible. * Tumor size as assessed on MRI. * On tumor biopsy: * Bloom-Richardson grade 1 or 2. * Non-lobular invasive histological type carcinoma. * LCIS or (non-extensive) DCIS is accepted. * ER positive tumor receptor. * HER2 negative tumor. * Tumor-negative sentinel node (excluding isolated tumor cells). * Adequate communication and understanding skills of the Dutch language. Exclusion Criteria: * Legal incapacity. * BRCA1, BRCA2 or CHEK2 gene mutation. * Distant metastasis. * Previous history of breast cancer or DCIS. * Other type of malignancy within 5 years before breast cancer diagnosis. Patients with adequately treated malignancy longer than 5 years before breast cancer diagnosis are eligible for inclusion. * For adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin no specific time span to breast cancer diagnosis is required for inclusion. * Collagen synthesis disease. * Signs of extensive DCIS component on histological biopsy or on imaging (e.g. no extensive calcifications on mammography). * Invasive lobular carcinoma. * MRI absolute contraindications as defined by the Department of Radiology. * Nodal involvement with cytological or histological confirmation. * Indication for treatment with (neo-)adjuvant chemotherapy. * Non-feasible dosimetric RT plan.
Conditions Anatomic Stage III Breast Cancer AJCC v8...
Phase PHASE1
Enrollment 45
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase I trial tests the safety, side effects, and best dose of ZEN003694 when given together with abemaciclib in treating patients with NUT carcinoma, breast cancer or other solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that overproduce BET protein. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ZEN003694 and abemaciclib may help shrink or stabilize cancer in patients with NUT carcinoma, breast cancer or other solid tumors.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Abemaciclib — Given PO
  • Drug: BET Bromodomain Inhibitor ZEN-3694 — Given PO
  • Procedure: Biopsy Procedure — Undergo biopsy
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Diagnostic Imaging Testing — Undergo imaging evaluation

Primary Outcomes

  • Maximum tolerated dose or recommended phase 2 dose (Phase I dose escalation) (During the first cycle of therapy (28 days))
  • Incidence of adverse events (Phase I dose expansion) (Up to 5 years)
  • Overall response rate (Phase I dose expansion) (Up to 5 years)
  • Clinical benefit rate (CBR) (Phase I dose expansion) (Up to 5 years)
  • Duration of response (DoR) (Phase I dose expansion) (From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 5 years)
  • Time to response (Phase I dose expansion) (From the time initiation of therapy to the time measurement criteria are met for CR or PR (whichever is first recorded), assessed up to 5 years)
  • Overall survival (Phase I dose expansion) (From study enrollment until death due to any cause, assessed up to 5 years)
  • Progression free survival (Phase I dose expansion) (From study enrollment until the identification of disease progression or death, assessed up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-08-10
Completion: 2027-06-07
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute (NCI)
Principal Investigators:
  • Jia Luo (PRINCIPAL_INVESTIGATOR) - Dana-Farber - Harvard Cancer Center LAO
Contact Information
Study Contact:
Site Public Contact
213-388-0908
Keck Medicine of USC Koreatown
Robert Hsu
Keck Medicine of USC Koreatown
Site Public Contact
323-865-0451
uscnorrisinfo@med.usc.edu
Los Angeles General Medical Center
Interventions
  • Drug: Abemaciclib — Given PO
  • Drug: BET Bromodomain Inhibitor ZEN-3694 — Given PO
  • Procedure: Biopsy Procedure — Undergo biopsy
  • Procedure: Biospecimen Collection — Undergo blood sample collection
  • Procedure: Diagnostic Imaging Testing — Undergo imaging evaluation
Study Locations (7 sites)
Keck Medicine of USC Koreatown, Los Angeles, California 90020 United States
Los Angeles General Medical Center, Los Angeles, California 90033 United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California 92663 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232 United States
UT MD Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Participants must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective * Dose Escalation Cohort Only: Participants must have evaluable disease or measurable disease per RECIST 1.1 criteria * Dose Expansion Cohort Only: * Participants must have a diagnosis of NUT carcinoma (NC) based on standard criteria for the disease, with diagnostic testing performed in a Clinical Laboratory Improvement Act (CLIA) certified laboratory: * Ectopic expression of NUT protein per World Health Organization (WHO) criteria as determined by immunohistochemistry (IHC) testing, OR * Detection of the NUT gene translocation as determined by fluorescence in situ hybridization (FISH) testing, OR * Detection of the NUT gene translocation as determined by either deoxyribonucleic acid (DNA) next-generation sequencing (NGS) or ribonucleic acid (RNA) sequencing. * Participants must have measurable disease per RECIST 1.1 criteria * Any number of prior lines of therapy in the metastatic setting are allowed, including prior BET inhibitor therapy and prior CDK4/6 inhibitor therapy * Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] grade =\< 1) from the acute effects of chemotherapy except for residual alopecia or grade 2 peripheral neuropathy * Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy * Participants may have previously undergone surgical resection * Age \>= 12 years. Patients 12-17 years of age must be \> 40 kg at enrollment. Patients 12-17 years of age will not participate in the mandatory tumor biopsies. Since there is no data on patients less than 18 years of age, this population may require lower doses and additional safety precautions and should be closely monitored. Because no dosing or adverse event data are currently available on the use of ZEN003694 in combination with abemaciclib in patients \< 12 years of age, younger children are excluded from this study * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 for participants \>= 16 years of age, Lansky \>= 50% if \< 16 years of age * Hemoglobin \>= 8 g/dL; Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion * Absolute neutrophil count \>= 1.5 x 10\^9/L * Platelets \>= 1 x 10\^11/L * Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) for age. Patients with Gilbert's syndrome with a total bilirubin =\< 2.0 times ULN and direct bilirubin within normal limits are permitted * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional ULN for age * Serum or plasma creatinine =\< 1.5 x institutional ULN OR calculated creatinine clearance \>= 50 mL/min (via the chronic kidney disease epidemiology \[CKD-EPI\] glomerular filtration rate estimation) for participants \>= 18 years old, or 60 mL/min/1.73m\^2 for patients 12-17 years as calculated based on bedside Schwartz formula * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. Hepatitis C (HepC antibody) testing is required. Hepatitis C RNA is optional; however, a confirmatory negative Hepatitis C RNA test must be obtained to be able to enroll participants with positive Hepatitis C antibody due to prior resolved disease * Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and has been clinically stable for at least 1 month. Patients must meet the following criteria: * Disease outside the CNS is present * Recovery from acute toxicity associated with the treatment to =\< CTCAE grade 1 or baseline (with the exception of alopecia), with no requirement for escalating doses of corticosteroids over the past 7 days * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients should be New York Heart Association Functional Classification of class 2B or better * Ability to swallow and retain oral medications * The effects of ZEN00364 and abemaciclib on the developing human fetus are unknown. For this reason and because BETi and CDKi-inhibiting agents are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Women of child-bearing potential must have a negative pregnancy test prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men and women treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 weeks after completion of ZEN003694 and abemaciclib administration * For female subjects of child-bearing potentially receiving ZEN003694, hormonal means of birth control alone, such as oral, injectable, dermal, subdermal or topical contraceptives are NOT acceptable forms of birth control given that their efficacy has not been evaluated when given in combination with the investigational drugs. "Adequate contraception" is defined as the following: * Contraceptive methods with a failure rate of =\< 1% used in combination with the barrier method. The following contraceptive methods are acceptable to use in combination with the barrier method: intrauterine device (IUD), intrauterine system (IUS), or oral contraceptive pills (OCPs) that meet the \< 1% failure rate as stated in the product label. Note: Hormonal IUDs/OCPs may only be used if the following criteria are met: male condoms are required AND subjects are informed of the potential for reduced systemic hormone levels from the IUD/OCP when taking ZEN003694. Alternatively, male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. For this definition, "documented" refers to the outcome of the investigator's/designee's medical examination of the subject or review of the subject's medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject's medical records * Male subjects with female partners of child-bearing potential must use one of the following contraceptive methods: * Vasectomy with documentation of azoospermia OR * Condom use PLUS partner use of a highly effective contraceptive (=\< 1% rate of failure per year) such as intrauterine device or system, or hormonal birth control such as contraceptive subdermal implant, combined estrogen and progestogen oral contraceptive, injectable progestogen, contraceptive vaginal ring, or percutaneous contraceptive patches * Male subjects should not donate sperm while on study and for 12
Conditions Breast Cancer Invasive, Metastatic Cance...
Phase PHASE2
Enrollment 56
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Patients with oligoprogression of metastatic breast cancer during palliative treatment that is amenable to local therapy will be included. The local ablative therapy (LAT) may consist of stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy, surgery or percutaneous ablation.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Surgery — resection of the oligometastatic lesion(s)
  • Radiation: Radiotherapy — radiation of the oligometastatic lesion(s)
  • Other: Radiofrequent ablation — radiofrequent ablation of the oligometastatic lesion(s)

Primary Outcomes

  • Number of patients free of progression at 6 months (At 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-04-17
Completion: 2040-04-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 56 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Netherlands Cancer Institute
Collaborators: Maarten van de Weijden Foundation
Principal Investigators:
  • G Sonke (PRINCIPAL_INVESTIGATOR) - The Netherlands Cancer Institute
Contact Information
Study Contact:
G Sonke, MD
+31-20-512
g.sonke@nki.nl
Robin van den Borg, MD
r.vd.borg@nki.nl
S Vrijaldenhoven, MD
Noordwest Ziekenhuisgroep
Interventions
  • Procedure: Surgery — resection of the oligometastatic lesion(s)
  • Radiation: Radiotherapy — radiation of the oligometastatic lesion(s)
  • Other: Radiofrequent ablation — radiofrequent ablation of the oligometastatic lesion(s)
Study Locations (7 sites)
Noordwest Ziekenhuisgroep, Alkmaar, Netherlands
Antoni van Leeuwenhoek, Amsterdam, Netherlands
Rijnstate, Arnhem, Netherlands
Deventer ziekenhuis, Deventer, Netherlands
ADRZ, Goes, Netherlands
Martini ziekenhuis, Groningen, Netherlands
Antonius ziekenhuis, Utrecht, Netherlands
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed invasive breast cancer * Metastatic breast cancer * o Oligoprogression is defined as an increase of ≥20% in size or, in case of FDG-PET-CT, metabolic activity (≥20% in SUVmax) involving a maximum of two lesions. These lesions may consist of: 1 or 2 distant metastatic lesions limited to 1 organ, the primary tumor or locoregional lymph nodes. * Systemic treatment can be either endocrine, targeted, chemotherapy or immune-checkpoint blockade * Patients should be on systemic therapy for at least six months. Status should be stable disease or partial or complete response for at least 6 months. * Oligoprogression has to be detected with radiological imaging comparing the lesion on the same type of imaging modality as has been used at the start of systemic therapy. * Lesion(s) must be amenable to resection, radiotherapy or percutaneous ablation with the intent of local obliteration. * The radiological imaging that shows progression must be performed within 70 days prior to LAT. * Bone metastases are classified as progressive if the lytic component of the lesion increases by ≥20% or the FDG-uptake increases by ≥20% on FDG-PET-CT * Lymph nodes should be larger than 15 mm upon first detection of oligoprogression to be classified as progressive. * Oligo-progression has to be confirmed with a FDG-PET-CT-scan 5-7 weeks after the initial scan that showed oligoprogression. * Age ≥18 * World Health Organization (WHO) Performance Status 0 or 1 * Signed written informed consent before patient registration according to ICH/GCP, and national/local regulations Exclusion Criteria: * Having received more than two lines of systemic therapy for MBC If a treatment regimen has been de-escalated without adding other therapies, this is seen as one line of therapy. For example: Pertuzumab/trastuzumab+docetaxel followed by pertuzumab/trastuzumab will be viewed as one line of systemic therapy. * Other malignancy except carcinoma in situ and basal-cell and squamous cell carcinoma of the skin, unless the other malignancy was treated ≥5 years ago with curative intent without the use of chemotherapy or radiation therapy * Current pregnancy or breastfeeding. Women of childbearing potential must use adequate contraceptive protection * Presence of any medical condition that would place the patient at unusual risk, up to the discretion of the clinician * Presence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Conditions Neurobehavioral Components of Reward and...
Phase NA
Enrollment 252
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study examines how people respond to rewards and losses, and the extent to which these responses are linked or distinct among people experiencing depressed mood, anhedonia, and/or anxiety.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: cognitive behavioral therapy — cognitive behavioral therapy
  • Behavioral: valuation with instruction — repeat laboratory sessions of computerized learning game
  • Behavioral: valuation without instruction — repeat laboratory sessions of computerized learning game

Primary Outcomes

  • change in proportion correct on the 'N-arm bandit learning task' (study entrance to study exit, an average of 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-08-01
Completion: 2027-07
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: false
Enrollment: 252 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Virginia Polytechnic Institute and State University
Contact Information
Study Contact:
Pearl Chiu, PhD
540-526-2032
chiup@vtc.vt.edu
Fralin Biomedical Research Institute at Virginia Tech Carilion
Interventions
  • Behavioral: cognitive behavioral therapy — cognitive behavioral therapy
  • Behavioral: valuation with instruction — repeat laboratory sessions of computerized learning game
  • Behavioral: valuation without instruction — repeat laboratory sessions of computerized learning game
Study Locations (1 sites)
Fralin Biomedical Research Institute at Virginia Tech Carilion, Roanoke, Virginia 24014 United States
Eligibility Criteria
Inclusion Criteria: * mood, anxiety, or anhedonia symptoms that affect functioning; fluent in English; able to see computer display; able to perform simple computer games. Exclusion Criteria: * history of seizure disorder, stroke, or head injury with more than 10 minutes of unconsciousness; hormone disorder; electroconvulsive therapy within 5 years; history of chemotherapy for cancer; current pregnancy; contraindications to MRI